HOME >> BIOLOGY >> NEWS
JCI Table of contents August 1, 2005

p?id=23076

ACCOMPANYING COMMENTARY:

TITLE: Weaving beta Klotho into bile acid metabolism

AUTHOR CONTACT:
Steven Kliewer
University of Texas Southwestern Medical Center, Dallas, TX USA
Phone: 214-645-6304; Fax: 214-645-6305; E-mail: steven.kliewer@utsouthwestern.edu

View the PDF of this article at: https://www.the-jci.org/article.php?id=26046

PHYSIOLOGY
Insulin spares intensive care patients from organ failure and death

It was previously shown, in a large, randomized, controlled trial that controlling blood glucose with insulin reduces the risk of organ failure and death of patients in intensive care. But the underlying mechanisms explaining these clinical benefits remained incompletely understood.

In a new study appearing on August 1 in The Journal of Clinical Investigation, the same group, Greet Van den Berghe and colleagues from Katholieke Universitiet Leuven, show that there is disturbed microcirculation in these patients that is due to endothelial dysfunction which causes inadequate oxygen supply to the cellular systems. The endothelium controls vascular flow and trafficking of important biological molecules. The endothelium of patients with prolonged critical illness is protected by strict blood glucose control with insulin and this may play a major role in the prevention of organ failure and death with this treatment.

This data may open perspectives for novel treatments and for progress in intensive care medicine. In an accompanying commentary, Dandona, et al write, "the results suggest a new paradigm in which glucose and insulin are related not only through their metabolic actions but also through their opposite effects on inflammatory mechanisms."

TITLE: Intensive insulin therapy protects the
'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
1-Aug-2005


Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology news :

1. JCI Table of Contents -- July 2, 2007
2. JCI Table of Contents: July 13, 3006
3. JCI Table of Contents, June 15 2006
4. JCI Table of Contents, April 13, 2006
5. JCI Table of Contents, March 1, 2005
6. JCI table of contents: Aug. 9, 2007
7. JCI table of contents: August 1, 2007
8. JCI table of contents -- July 26, 2007
9. JCI table of contents: July 19, 2007
10. JCI table of contents: July 12, 2007
11. JCI table of contents: June 21, 2007

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
Cached News: